Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences

References

• Cohen A, Doveh E, Umansky T. 2001. How to assess the relative range of two consecutive laboratory measurements to monitor patients. J Biopharm Stat 11:177–191.
   PubMedGoogle Scholar
• DeLong ER, Vernon WB, Bollinger RR. 1985. Sensitivity and specificity of a monitoring test. Biometrics 41:947–958.
   PubMedGoogle Scholar
• Emir B, Wieand S, Su JQ, Cha S. 1998. Analysis of repeated markers used to predict progression of cancer. Stat Med 17:2563–2578.
   PubMed Web of Science ®Google Scholar
• Fraser CG. 2004. Inherent biological variation and reference values. Clin Chem Lab Med 42:758–764.
   PubMed Web of Science ®Google Scholar
• Fukuda I, Vamakado M, Kiyose H. 1998. Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services. J Med Syst 22:89–93.
   PubMedGoogle Scholar
• Gion M, Cappelli G, Mione R, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M. 1993. Variability of tumor markers in the follow-up of patients radically resected for breast cancer. Tumour Biol 14:325–333.
   PubMedGoogle Scholar
• Gion M, Cappelli G, Mione R, Pistorello M, Meo S, Vignati G, Fortunato A, Saracchini S, Biasioli R, Giulisano M. 1994. Evaluation of critical differences of CEA and CA 15.3 levels in serial samples from patients operated for breast cancer. Int J Biol Markers 9:135–139.
   PubMedGoogle Scholar
• Gion M, Barioli P, Mione R, Cappelli G, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M. 1995. Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Forza Operativa Nazionale sul Carcinoma Mammario (FONCaM). Ann Oncol 6:31–35.
   Google Scholar
• Gion M, Peloso L, Mione R, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M, Cappelli G. 2001. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J 7:181–190.
   PubMedGoogle Scholar
• Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, Gatti C, Paccagnella A, Marubini E. 2002. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38:1165–1166.
   PubMedGoogle Scholar
• Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312.
   PubMed Web of Science ®Google Scholar
• Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P. 2007. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 27:1963–1968.
   PubMed Web of Science ®Google Scholar
• Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M, Ballesta AM. 1995. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36:41–48.
   PubMed Web of Science ®Google Scholar
• Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, Farrus B, Ballesta AM. 2003. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 23:1035–1041.
   PubMedGoogle Scholar
• Molina R, Barak V, Van Dalen A, Duffye MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. 2005. Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. Tumor Biol 26:281–293.
   PubMedGoogle Scholar
• Nicolini A, Carpi A, Ferrari P, Anselmi L.1997a. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts. Int J Biol Markers 12:181–186.
   PubMedGoogle Scholar
• Nicolini A, Anselmi L, Michelassi C, Carpi A.1997b. Prolonged survival by ‘early’ salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 76:1106–1111.
   PubMed Web of Science ®Google Scholar
• Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P, Fini M, Giardino R.2003a. ‘Tumour marker guided’ salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother 57:452–459.
   PubMedGoogle Scholar
• Nicolini A, Carpi A, Ferrari P, Pieri L.2003b. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol 24:275–280.
   PubMedGoogle Scholar
• Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, Lee KS. 2008. Preoperative CA 153 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 19:675–681.
   PubMed Web of Science ®Google Scholar
• Queraltó JM. 2004. Intraindividual reference values. Clin Chem Lab Med 42:765–777.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Egger M, Saunders MP, O’Dwyer ST. 2002. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324:813–825.
   PubMed Web of Science ®Google Scholar
• Riffenburgh RH, Cummins KM. 2006. A simple and general change-point identifier. Stat Med 25:1067–1077.
   PubMed Web of Science ®Google Scholar
• Seregni E, Coli A, Mazzucca N. 2004. Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 31:S15–S22.
   Google Scholar
• Sölétormos G, Nielsen D, Schiøler V, Skovsgaard T, Dombernowsky P. 1996. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 42:564–575.
   PubMed Web of Science ®Google Scholar
• Sölétormos G, Nielsen D, Schiøler V, Mouridsen H, Dombernowsky P. 2004. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 40:481–486.
   PubMedGoogle Scholar